Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06350331
Enrolling by invitation Not applicable

Smart Technology Facilitated Patient-centered Venous Thromboembolism Management

NCT06350331 · tracked via the Priya Life Science China tracker
Sponsor
Navy General Hospital, Beijing
Phase
Not applicable
Started
2024-08-17
Last updated
2025-05-31

Condition(s) studied

Venous ThromboembolismDigital HealthHealth Education

Investigational drug(s) / intervention(s)

mobile venous thromboembolism application (mVTEA)

mobile venous thromboembolism application (mVTEA): mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.

Study summary

Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.

The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on patients' perceptions of thromboprophylaxis, in order to enhance clinical practice and establish a foundation of evidence for managing patients with VTE.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Inpatients ≥18 years of age at admission; * Previous or current definitive diagnosis of DVT and/or PE by imaging, or at high risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients. * Signed informed consent Exclusion Criteria: * Mental disorder or combination of other serious diseases leading to incapacity for independent living; * Inability to use smartphones, computer tablets and other smart devices; * Being pregnant or breastfeeding; * Have participated in similar trials or are undergoing other clinical trials.

Primary outcome measure(s)

  • VTE-KAP questionnaire score — The third month after discharge from the hospital
    The VTE-KAP questionnaire is a self-administered questionnaire that includes demographic characteristics, knowledge, attitude, and practice (KAP) of patients towards VTE prevention and treatment. The VTE-KAP questionnaire consists of a total of 53 questions with an overall score range of 41 to 283. The higher the score, the higher the level of knowledge, attitude, and practice. The VTE-KAP questionnaire scores will be evaluated at the third-month follow-up after discharge.

Trial sites (1)

FacilityCityRegionStatus
Sixth Medical Center of Chinese PLA General Hospital Beijing Beijing Municipality

More Navy General Hospital, Beijing trials in China

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS Recruiting
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management Starting soon
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Recruiting
Effect of Aerobic Interval Training on Atrial Fibrillation Burden Starting soon
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas Recruiting

Other trials for the same condition

Therapy on Perioperative Anxiety and Pain in Patients Recruiting
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management Starting soon
Prevention of Ischemic Stroke Recurrence Using Digital Technology Application Starting soon
Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery Active, not recruiting
Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06350331 on ClinicalTrials.gov ↗ ← All trials in China